HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and first-line chemotherapy. In this study, we delineate that KRAS-mutant lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haitang, Liang, Shun-Qing, Xu, Duo, Yang, Zhang, Marti, Thomas M., Gao, Yanyun, Kocher, Gregor J., Zhao, Heng, Schmid, Ralph A., Peng, Ren-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702198/
https://www.ncbi.nlm.nih.gov/pubmed/31431614
http://dx.doi.org/10.1038/s41389-019-0158-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702198/
https://www.ncbi.nlm.nih.gov/pubmed/31431614
http://dx.doi.org/10.1038/s41389-019-0158-7

Ejemplares similares